Important Notice for Actinium Pharmaceuticals, Inc. Shareholders
New York, April 10, 2025 – The Gross Law Firm, a leading national securities fraud law firm, issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM).
If you purchased shares of Actinium Pharmaceuticals, Inc. (ATNM) during the class period of February 1, 2023, and February 28, 2025, you may have been affected by alleged securities fraud, and you are encouraged to contact the firm.
Background
Actinium Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of therapies for various types of cancer. The company’s lead product candidate, I-131 Apastin, is a targeted radiotherapeutic designed to treat relapsed or refractory acute myeloid leukemia (r/r AML).
Allegations of Securities Fraud
The Gross Law Firm alleges that Actinium Pharmaceuticals, Inc. and certain of its executives and directors made false and misleading statements regarding the company’s financial condition, business prospects, and clinical trial results, specifically related to I-131 Apastin.
Class Action Lawsuit
The Gross Law Firm, on behalf of the shareholders, filed a class action lawsuit against Actinium Pharmaceuticals, Inc. in the United States District Court for the Southern District of New York. The complaint alleges that the defendants violated the Securities Exchange Act of 1934 and seeks to recover damages on behalf of the shareholders.
Possible Impact on Shareholders
If the allegations against Actinium Pharmaceuticals, Inc. are proven, shareholders who purchased shares during the class period may be able to recover their losses through the class action lawsuit.
Global Implications
This incident highlights the importance of transparency and honesty in the biopharmaceutical industry. Misrepresentations of clinical trial results or financial data can significantly impact investors, potentially leading to substantial financial losses. It also underscores the need for robust regulatory oversight and effective enforcement mechanisms to protect investors.
Conclusion
If you purchased shares of Actinium Pharmaceuticals, Inc. during the class period and believe you may have been affected by the alleged securities fraud, we encourage you to contact The Gross Law Firm as soon as possible. Your potential recovery could be substantial. We are committed to seeking justice on behalf of our clients and ensuring accountability for those who mislead investors.
As a responsible investor, it is crucial to stay informed about the companies you invest in and to be aware of any potential risks. This case serves as a reminder that transparency and honesty are essential in the investment world, and that shareholders have legal recourse when they are misled.
- Contact The Gross Law Firm if you purchased shares of Actinium Pharmaceuticals, Inc. during the class period.
- Stay informed about the companies you invest in.
- Demand transparency and honesty from companies and their executives.
